Medipost(35,350 -13.99%)And LG Chem(806,000 +1.13%)Announced on the 23rd that it has signed a technology transfer contract for Medipost’s high-efficiency cell culture platform technology’MLSC’. The amount is private.
From the end of 2018, the two companies signed a joint research contract to discover new drug candidates, and jointly conducted basic research for the development of gene cell therapy products.
Under the contract, Medipost grants LG Chem a license to use related technologies such as high-efficiency mesenchymal stem cells and MLSC, a high-efficiency cell culture platform technology. Based on this, LG Chem plans to expand the development of candidate materials for innovative gene cell therapy products. MLSC is a next-generation stem cell platform technology that can mass-produce high-efficiency cells.
Medipost will receive a down payment with no return condition. In the future, LG Chem will sequentially receive incentives (milestones) according to sales at the time of global clinical development progress and commercialization. In addition, it will additionally receive current technology fees (royalties) based on net sales. LG Chem will have the exclusive right to develop and commercialize gene cell therapy products discovered through joint research by both companies.
Yang Yun-seon, CEO of Medipost, said, “With the active cooperation of the two companies, we were able to discover the optimal candidate material for gene cell therapy.” “Because this technology transfer is a non-exclusive license for cell culture platform technology, additional technology transfer is possible.” Said.
“We have confirmed the possibility of development as an innovative gene cell therapy through two years of joint research,” said Ji-woong Sohn, head of the Life Science Business Division of LG Chem. “We plan to release it.”
Reporter Minsoo Han [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution